The key molecular mechanism for this type of anti-tumor drug is the inhibition of cyclooxygenase (COX) pathway, whose center components include cyclooxygenase-2 (COX-2), cytosolic glutathione transferases (GSTM2, 3), and prostaglandin E2 (PGE2). This evidence concerns the gene PTGS2 and neoplasm.